FMR LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 10:34 am Purchase | 2024-11-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 7,623,881 14.999% | 1,040,726 (+15.81%) | Filing |
| 2024-06-10 09:48 am Sale | 2024-06-07 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,583,155 12.963% | -1,020 (-0.02%) | Filing |
| 2024-03-11 08:19 am Purchase | 2024-03-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,584,175 18.213% | 377,724 (+6.09%) | Filing |
| 2024-02-12 12:03 pm Purchase | 2024-02-09 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,206,451 13.065% | 2,420,574 (+63.94%) | Filing |
| 2024-02-09 10:20 am Purchase | 2024-02-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 3,785,877 7.969% | 3,785,877 (New Position) | Filing |